News and Resources

Recent Developments Newsreel


  • In Moscow, we have expanded our dedicated office space adjoining our parent companies in the Arbat Business Center. We would love to have your study management team in for a visit!

  • In the past 6 months, AmeRuss has put dedicated CRA staffing in place in our regional offices for South Siberia and Ural Regions. These assignments will vastly improve our operational efficiencies in these federal districts. AmeRuss has recently initiated our portion of an exciting global rheumatology trial for one of the world's largest Pharmaceutical companies with six sites in these regions.

  • AmeRuss has completed the development of a first-in-human/first-in-patient protocol of a novel neurotoxin for pain and inflammation for a small US pharmaceutical manufacturer. While the implementation of the protocol must await further animal pre-clinical safety analyses, this exciting compound may fill a huge unmet need in this arena.

  • AmeRuss may oversee the world's final subject in Belarus for a protocol involving a potential significant advance in the management of a rare thyroid cancer. The data is being carefully analyzed in a run-up to a global presentation.

  • New legislation is under development that will standardize medical device trial conduction in Russia for widespread implementation at certified investigational sites. Our Acting Country Manager Dr. Andrei Bazarov currently provides consultation to a working committee to advise the legislation. Until this legislation is enacted in Q1 or Q2 2011, medical device trails may be conducted a several key scientific centers throughout the Russian Federation through a traditionally accepted oversight process. Currently AmeRuss is supporting the development of a revolutionary device for optimizing cardiac valve leaflet closure using a closed heart system. Our client hails from the hotbed cluster of medical device development in Israel.

  • As AmeRuss grows towards ultimate leadership in regional expertise in pharmaceutical, biopharmaceutical and medical device trial conduction, we look forward to the next opportunity to discuss your clinical development needs in the best of East Europe.

Primus Flavocoxid Pilot Trial Published

     Follow link to view National Center for Biotechnology Information abstract:



Primus Flavocoxid Pivotal Trial Published

     Follow link to view National Center for Biotechnology Information abstract:


Primus Flavocoxid Abstract Accepted

AmeRuss congratulates Primus Pharmaceuticals, Inc. on the acceptance of its abstract "Safety and Efficacy of Flavocoxid Compared with Naproxen in Subjects with Osteoarthritis of the Knee: A Pilot Study" for presentation at the 7th World Congress of the International Cartilage Repair Society in Warsaw in September 2007. AmeRuss assisted Primus in the conduction of this protocol in Russia.


OXiGENE Zybrestat presenting at International Thyroid Congress 

SOUTH SAN FRANCISCO, Calif., June 24, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that data from its clinical trials of ZYBRESTAT and chemotherapy in patients with anaplastic thyroid cancer (ATC), will be presented at the upcoming 14th International Thyroid Congress in Paris, France, on September 12, 2010.  OXiGENE will release a summary of results immediately after they are presented.


CRO's in Eastern Europe and Beyond

Clinical Trials in Eastern Europe

Clinical Trials in Russia (2010 Q2 Orange Paper)


Learn More about the Origins of ICH-GCP

Official Web Site for ICH

The World Medical Association Declaration of Helsinki

Guidance for Industry Acceptance of Foreign Clinical Studies